Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Understanding CRISPR: Mechanisms and Applications: CHI, September 19-22, 2016, Westin Boston Waterfront, Boston

Reporter: Aviva Lev-Ari, PhD, RN

PRELIMINARY AGENDA NOW AVAILABLE!

Registration & Pricing | Sponsorship & Exhibit Opportunities | Visit Website

http://www.discoveryontarget.com/crispr-therapies/

ABOUT THIS SYMPOSIUM:

Gene editing is rapidly progressing from being a research/screening tool to one that promises important applications downstream in drug development, cell and gene therapy. Cambridge Healthtech Institute’s symposium on Understanding CRISPR: Mechanisms and Applications will bring together experts from all aspects of basic science and clinical research to talk about how gene editing works and where it can be best applied. What are the different tools that can be used for gene editing, and what are their strengths and limitations? How does the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system compare to Transcription Activator-like Effector Nucleases (TALENs), zinc finger nucleases (ZFNs) and other alternative CRISPR-based systems? What do we now know about the biology of CRISPR and what lessons have we learnt from working with RNA interference (RNAi)-based systems? Scientists and clinicians from pharma/biotech as well as from academic and government labs will discuss the new findings in CRISPR mechanisms and share their experiences leveraging the utility of CRISPR-based gene editing for functional screening, disease modeling, and for creating cell and viral therapies.

PRELIMINARY AGENDA

SETTING UP FUNCTIONAL SCREENS USING CRISPR/CAS9

Comparing Arrayed siRNA and CRISPR Approaches Towards Functional Genomics Screening
Scott Martin, Ph.D., Group Lead, Functional Genomics, Genentech Inc.

Getting from Alpha to Omega: Successfully Conceptualizing, Starting and Finishing CRISPR/Cas Screens
Ralph Garippa, Ph.D., Director, RNAi Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

Early Lessons in Shifting Systems: RNAi and CRISPR/Cas9 Functional Genomic Screens in Lymphoma
Arthur L. Shaffer, III, Ph.D., Staff Scientist, Laboratory of Dr. Louis Staudt, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

PANEL DISCUSSION: Will Interference from CRISPR Silence RNAi?
Participants: Session Speakers

EMERGING APPLICATIONS OF CRISPR/CAS9

Live-Cell Imaging of Genomic Loci Using CRISPR/Cas and RNA Aptamers
Adam Cawte, Postgraduate Student, MRC Clinical Science Centre, Imperial College London

MicroRNA Target Site Editing of Chondrocyte Master-Regulators in Primary Human Cells Using CRISPR-Cas9
Christine Seidl, Ph.D., Post-Doctoral Research Associate, Cell Signaling, Kennedy Institute of Rheumatology, Oxford University

GENE EDITING FOR EXPLORING NOVEL TARGETS & THERAPIES

Genome Editing-Enabled HTS Assays for Genetically Inherited Disease Drug Discovery
James Inglese, Ph.D., Head Assay Development & Screening Technologies, National Center for Advancing Translational Sciences, NIH

Massively Parallel Combinatorial Genetic Perturbation Screening with CRISPR-Cas9 in Human Cells

Cheryl H. Cui, Ph.D. Candidate, Harvard-MIT Division of Health Science and Technology, MIT

Stay on to attend back-to-back conferences (September 20-21 and September 21-22)

Advances in Gene Editing and Gene Silencing – Part 1 and Part 2

For more details on the conference, please contact:

Tanuja Koppal, Ph.D.

Conference Director

Cambridge Healthtech Institute

E: tkoppal@healthtech.com

For sponsorship and exhibit sales information including sponsored podium presentations, contact:

Jon Stroup

Sr. Business Development Manager

Cambridge Healthtech Institute

T: (+1) 781-972-5483

E: jstroup@healthtech.com

Cambridge Healthtech Institute

250 First Avenue, Suite 300 | Needham, MA 02494 | P: 781.972.5400 | E: chi@healthtech.com

www.healthtech.com

SOURCE

From: CHI Conferences <bethanyg@healthtech.com>

Date: Wednesday, April 6, 2016 at 8:45 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Preliminary Agenda Available: Understanding CRISPR: Mechanisms and Applications